Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end the alliance.

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for malaria prevention.

Several scientists studying LGBTQ+ health issues have had their grants from the National Institutes of Health canceled effective immediately, according to a March 3 report from Stat.

Private equity giant Blackstone is going big on Japan, acquiring a majority stake in the country’s leading contract research organization.

Beginning in late May, BMS will lay off 223 workers in Lawrenceville, New Jersey, where the company hosts its corporate headquarters, as well as a facility for commercial and late-stage development work. Separately, the company is laying off 57 employees at a research site in California. The downsizing initiative is part of BMS’ broader effort to cut costs.

The VA said its cuts are the “first step” in its audit of the roughly 90,000 contracts it currently has in place—a process its announcement stressed is being conducted with in-house expertise and feedback. Specific plans for the savings will be shared "in the coming weeks and months," the department said.